AstraZeneca acknowledges its Covid-19 vaccine can cause Thrombosis with Thrombocytopenia Syndrome (TTS) after a lawsuit alleging severe harm and deaths. Covishield, developed by AstraZeneca and Oxford University and produced by the Serum Institute of India, can rarely lead to this condition.
ये जो अक्सर आप हार्ट अटैक से मौत की खबरें पड़ते हो उन पर शक पहले से ही था अव तो शक विश्वास में बदल गया !!
बिना परखे ये सब कैसे और क्यों हुआ??#covaxin #Covishield pic.twitter.com/JoMB2mJHjh
— ShivRaj Yadav (@shivayadav87_) April 30, 2024
What is Thrombosis with Thrombocytopenia Syndrome (TTS)?
Thrombosis with Thrombocytopenia Syndrome (TTS) is a rare condition where blood clots form in unusual places in the body and platelet count decreases. It’s observed in individuals who received adenoviral vector COVID-19 vaccines like Vaxzevria, Covishield (AstraZeneca), and Johnson & Johnson/Janssen vaccine. TTS is believed to occur due to the immune system’s response to the vaccine, causing antibodies to attack a blood clotting protein.
The CDC categorizes TTS into two tiers based on severity: Tier 1 involves rare blood clots in the brain or gut, along with more typical clots in the legs or lungs, often affecting younger individuals. Tier 2 includes more common blood clots in the legs or lungs.
Symptoms
Symptoms may include severe headaches, stomach pain, leg swelling, breathing difficulty, and cognitive issues or seizures. Immediate medical attention is advised for individuals experiencing these symptoms after vaccination.
Keep Reading
MP Balram Talab Yojana 2023: Farmers get support to build ponds
Will the Ken-Betwa project benefit the Bundelkhand region?
Follow Ground Report for Environmental News From India. Connect with us on Facebook, Twitter, Koo App, Instagram, WhatsApp and YouTube. Write to us at GReport2018@gmail.com and subscribe to our free newsletter.
Don’t forget to check out our climate glossary, and learn difficult environmental terms in simple language.
